Allergic Contact Dermatitis Clinical Trial
Official title:
Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study.
It is the purpose of this study to determine the concentration of 3 allergens (goldnatriumthiosulphate, methyldibromoglutharonitrile [MDBGN], parthenolide) for diagnosing allergic contact dermatitis.
The TRUE Test standard panel consists of two tape strips, panel 1 with 11 allergen patches and a negative control and panel 2, with 12 allergen patches. TRUE test panel 1 and 2 contain 23 of the most frequent contact allergens.With these 23 allergens, it is possible to detect about 60-70% of contact allergic reactions. Thus, there is a need for expanding the number of allergens included in TRUE Test in order to detect more contact allergic reactions. Therefore goldnatriumthiosulphate, methyldibromoglutharonitrile and parthenolide are developed for inclusion in a third TRUE Test panel. This study is a dose-response study using 3 dilution series to detect the optimum concentration of the 3 allergens. A phase-III study will be performed afterwards to establish the efficacy and safety of the three allergens. ;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03945760 -
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
|
Early Phase 1 | |
| Not yet recruiting |
NCT05498467 -
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
|
Phase 3 | |
| Active, not recruiting |
NCT03680131 -
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
|
Phase 2 | |
| Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06191627 -
Patient Experience and Quality of Patch Testing on the Legs vs Back
|
N/A | |
| Completed |
NCT00867607 -
Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00445029 -
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
|
N/A | |
| Completed |
NCT04365140 -
MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
|
||
| Recruiting |
NCT05991674 -
A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
|
||
| Completed |
NCT00931242 -
Study of Apremilast in Atopic or Contact Dermatitis
|
Phase 2 | |
| Completed |
NCT01798589 -
Bioequivalence of Ethylenediamine Dihydrochloride Study
|
Phase 4 | |
| Completed |
NCT01546298 -
Immune Reactions in Contact Dermatitis Affected Skin
|
||
| Completed |
NCT05339750 -
Allergy Skin Patch Artificial Intelligence (AI)
|
N/A | |
| Recruiting |
NCT03935971 -
The Effects of Dupilumab on Allergic Contact Dermatitis
|
Phase 4 | |
| Completed |
NCT01797562 -
Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
|
N/A | |
| Not yet recruiting |
NCT05858723 -
Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool
|
N/A | |
| Completed |
NCT02534441 -
Epidemiology and Co-Reactivity of Novel Surfactant Allergens
|
N/A | |
| Not yet recruiting |
NCT01413477 -
Nickel Desensitization Using Topical Therapy
|
N/A | |
| Completed |
NCT00132600 -
Clinical Evaluation of Bacitracin
|
Phase 2 | |
| Completed |
NCT03902392 -
Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
|
N/A |